What triggered the automatic tax-related share sale for Arvinas’ CMO?

The automatic sale was triggered by the vesting and settlement of one-half of the restricted stock units granted to the CMO on May 9, 2025. To satisfy associated tax withholding obligations, Arvinas arranged for 11,108 shares to be sold in the market.

Arvinas CMO sells shares to cover RSU taxes

Arvinas, Inc.’s Chief Medical Officer, Noah Berkowitz, reported a sale of 11,108 shares of common stock at an average price of $9.9374 per share on May 11, 2026.

Filing Impact

(Moderate)

Filing Sentiment

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Arvinas, Inc.’s Chief Medical Officer, Noah Berkowitz, reported a sale of 11,108 shares of common stock at an average price of $9.9374 per share on May 11, 2026. According to the filing, the sale was made automatically by the company to cover tax withholding obligations tied to the vesting and settlement of half of his RSUs granted on May 9, 2025, and is not a discretionary trade. Following this tax-related sale, Berkowitz directly holds 191,395 shares of Arvinas common stock.

Insider Trade Summary

Net Seller: 11,108 shares

Net Sell 1 txn

Insider Berkowitz Noah

Role Chief Medical Officer

Sold 11,108 shs ($110K)

Type	Security	Shares	Price	Value
Sale	Common Stock	11,108	$9.9374	$110K

Holdings After Transaction: Common Stock — 191,395 shares (Direct)

Footnotes (1)

F1. This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-half of the reporting person's restricted stock units (RSUs) granted on May 9, 2025. The sale does not represent a discretionary trade.

Key Figures

Shares sold: 11,108 shares Sale price: $9.9374 per share Post-transaction holdings: 191,395 shares +1 more

4 metrics

Shares sold 11,108 shares Automatic sale on May 11, 2026 to cover RSU tax withholding

Sale price $9.9374 per share Average price for 11,108 shares of Arvinas common stock

Post-transaction holdings 191,395 shares Arvinas common stock directly held by CMO after transaction

Transaction type Tax-related sale Automatic sale to cover tax withholding on vested RSUs

Key Terms

restricted stock units (RSUs), tax withholding obligations, vesting and settlement, discretionary trade

4 terms

restricted stock units (RSUs) financial

"in connection with the vesting and settlement of one-half of the reporting person's restricted stock units (RSUs) granted on May 9, 2025"

Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.

tax withholding obligations financial

"sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting"

vesting and settlement financial

"in connection with the vesting and settlement of one-half of the reporting person's restricted stock units"

discretionary trade financial

"The sale does not represent a discretionary trade"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Arvinas (ARVN) disclose for Noah Berkowitz?

Arvinas disclosed that Chief Medical Officer Noah Berkowitz had 11,108 shares of common stock sold on May 11, 2026. The shares were sold at an average price of $9.9374 each to satisfy tax withholding obligations related to vesting RSUs.

Was the Arvinas CMO’s recent stock sale a discretionary trade?

No, the sale was not discretionary. The filing states the shares were sold automatically by Arvinas to cover tax withholding obligations from the vesting and settlement of RSUs granted on May 9, 2025, rather than a voluntary open-market decision.

How many Arvinas (ARVN) shares did the CMO sell and at what price?

The Chief Medical Officer had 11,108 shares of Arvinas common stock sold at an average price of $9.9374 per share. This transaction was executed to cover tax withholding obligations associated with the vesting of restricted stock units.

How many Arvinas shares does Noah Berkowitz hold after the transaction?

After the tax-related sale, Noah Berkowitz directly holds 191,395 shares of Arvinas common stock. This post-transaction holding reflects his remaining equity position following the automatic sale to satisfy RSU-related tax withholding obligations.

Does the Arvinas Form 4 indicate any derivative or option exercises?

No, the Form 4 does not show any option or other derivative exercises. It only reports a single non-derivative common stock transaction, an automatic sale of 11,108 shares to cover tax withholding from RSU vesting and settlement.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 05/13/2026 - 04:16 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Berkowitz Noah

(Last)

(First)

(Middle)

C/O ARVINAS, INC.

5 SCIENCE PARK, 395 WINCHESTER AVE.

(Street)

NEW HAVEN

CONNECTICUT

06511

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ARVINAS, INC. [ ARVN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/11/2026		S		11,108⁽¹⁾	D	$9.9374	191,395	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-half of the reporting person's restricted stock units (RSUs) granted on May 9, 2025. The sale does not represent a discretionary trade.

Remarks:

	/s/ Jared Freedberg, as attorney-in-fact for Noah Berkowitz	05/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR